Oral heparin using a modified amino acid carrier: EMIS began a Phase I dose escalation study in 30 healthy volunteers.

The carrier is a small molecule modified amino acid for oral delivery of proteins. It is non-covalently bound to the protein to create the properties of a prodrug, changing the solubility and enzymati...